Sagent Pharmaceuticals
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 27.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$53.0m | Series A | ||
N/A | $30.0m | Series A | |
N/A | $30.0m | Series A | |
$40.0m | Series B | ||
N/A | N/A | IPO | |
N/A | $736m Valuation: $736m | Acquisition | |
Total Funding | AUD236m |
Related Content
Recent News about Sagent Pharmaceuticals
EditSagent Pharmaceuticals is a company that specializes in the development, manufacturing, and marketing of injectable pharmaceutical products. The company operates in the healthcare and pharmaceutical market, primarily serving hospitals, clinics, and healthcare providers. Sagent's business model revolves around creating high-quality, safe, and reliable injectable medications, which are essential for various medical treatments and procedures. The company generates revenue by selling these pharmaceutical products to healthcare institutions and through strategic partnerships. Sagent places a strong emphasis on safety, as evidenced by their PreventIV Measures initiative, which aims to enhance patient safety through innovative packaging and labeling solutions. The company's product portfolio includes a wide range of injectable medications, such as Esmolol Hydrochloride Injection, Daptomycin for Injection, and Metronidazole Injection, USP. Sagent also engages in continuous product updates and recalls to ensure the highest standards of quality and safety. The company operates on a global scale, leveraging its expertise in pharmaceuticals to meet the needs of healthcare providers worldwide.
Keywords: injectable pharmaceuticals, healthcare, safety, reliability, hospitals, clinics, patient safety, product recalls, global scale, strategic partnerships.